Results 131 to 140 of about 16,624 (211)

Remdesivir as a potent antiviral against prototype and current epidemic Oropouche virus strains (BeAn19991 and PE-IAM4637). [PDF]

Virus Res
Yoshikawa R, Ishii Y, Sano N, Yasuda J.
europepmc   +1 more source

In silico prediction, molecular docking and simulation of natural flavonoid apigenin and xanthoangelol E against human metapneumovirus. [PDF]

In Silico Pharmacol
Rahaman HH, Khan A, Sharif N, Ahmed W, Sharif N, Majumder R, Obregon SA, Iglesias RC, De la Torre Díez I, Dey SK.   +9 more
europepmc   +1 more source

Re-evaluating a single-arm trial of favipiravir for severe fever with thrombocytopenia syndrome in Japan: A proposal to use real-world data as external controls. [PDF]

PLoS Negl Trop Dis
Kubo K, Toyama M, Kobayashi KI, Komiya N, Nakayama T.   +4 more
europepmc   +1 more source

First therapeutic drug monitoring of experimental favipiravir in Borna disease virus 1 (BoDV-1) encephalitis patients reveals significant gaps in antiviral treatment: a pilot investigation. [PDF]

Eur J Med Res
Paal M, Habler K, Ewert A, Vogeser M, Grosse L, Lieftüchter V, Tauber SC, Schiefer J, Allartz P, Tappe D, Pörtner K.   +10 more
europepmc   +1 more source

REVIEW ON FAVIPIRAVIR

International Journal of Biology, Pharmacy and Allied Sciences, 2021
openaire   +1 more source

Exploration of African natural products as VP35 inhibitors to combat Marburg virus infection: Molecular docking, molecular dynamics, and quantum mechanical computations. [PDF]

PLoS One
Abdelrahman AHM, Mekhemer GAH, Sidhom PA, El-Tayeb MA, Khan S, Ibrahim MAA.   +5 more
europepmc   +1 more source

A quality-by-design optimized LC method for navigating degradation kinetics and quantification of favipiravir in the presence of degradation products and manufacturing impurities. [PDF]

BMC Chem
Ibrahim AE, Farouk M, Alamir SG, Salman BI, Belal TS, El Deeb S, Al-Harrasi A.   +6 more
europepmc   +1 more source

Clinical effectiveness, safety, and viral mutagenicity of oral favipiravir for COVID-19: results from a community-based, open-label, randomized Phase III trial. [PDF]

Antimicrob Agents Chemother
Tate M, Illingworth CJR, MacGregor G, Cunningham L, Divers L, McCartney E, Paterson L, Kelly C, Shaw A, Perkins JS, Silva V, Holland P, Dalton C, Carmichael S, Douglas E, Surtees P, Scott JT, Berry C, Vattipally S, Da Silva Filipe A, Tong L, Gunson R, GETAFIX trial co-investigators, McInnes IB, Jones R, Thomson E, Blyth KG.   +26 more
europepmc   +1 more source

A primary oseltamivir-resistant mutation in influenza hemagglutinin and its implications for antiviral resistance surveillance. [PDF]

Nat Commun
Zhang L, Shao Y, Zou X, Cui Y, Ding S, Chen Y, Wu Q, Mu S, Li X, Yang Q, Cao B, Deng T.   +11 more
europepmc   +1 more source